Sacituzumab govitecan-hziy is an antibody drug conjugate (ADC) that is indicated in locally advanced or metastatic urothelial cancer (mUC), triple negative breast cancer, and most recently approved for use in HR(+) HER2(-) breast cancer.1-3 The purpose of this PQI is to provide information on the management of common adverse events, follow-up with patients, and dose-modifications related to neutropenia and diarrhea.